Drug
ZD6126
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(50%)
Phase Distribution
Ph phase_2
2
100%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Terminated(1)
Other(1)
Detailed Status
Terminated1
Suspended1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
terminated150%
suspended150%
Recent Activity
0 active trials
Showing 2 of 2
terminatedphase_2
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
NCT00065117
suspendedphase_2
Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)
NCT00065572
Clinical Trials (2)
Showing 2 of 2 trials
NCT00065117Phase 2
Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
NCT00065572Phase 2
Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2